Anaplastic large cell lymphoma medical therapy

Jump to navigation Jump to search

Anaplastic large cell lymphoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Anaplastic large cell lymphoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Anaplastic large cell lymphoma medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Anaplastic large cell lymphoma medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Anaplastic large cell lymphoma medical therapy

CDC on Anaplastic large cell lymphoma medical therapy

Anaplastic large cell lymphoma medical therapy in the news

Blogs on Anaplastic large cell lymphoma medical therapy

Directions to Hospitals Treating Anaplastic large cell lymphoma

Risk calculators and risk factors for Anaplastic large cell lymphoma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Medical Therapy

  • Managed under "Aggressive Lymphoma" guidelines
    • CHOP is first line of treatment, CHOP-Rituxan in the unlikely scenario that CD20 is positive, given that CD20 is a B-cell marker.
    • Radiation therapy as per institutional preference (based on ECOG, SWOG, and GELA trials), but usually added for bulky disease
  • Overall better prognosis than other "Aggressive Lymphomas"
    • ALK+ 5-year survival 70-80%
    • ALK- 5-year survival 30-40%

References

Template:WH Template:WS